Anti-MERS-CoV Spike Glycoprotein Rabbit Monoclonal Antibody (Clone 723)

Middle East respiratory syndrome coronavirus (MERS-CoV) is an enveloped positive-stranded RNA virus and a member of the Betacoronavirus genus and causative agent of MERS, an acute respiratory disease that often leads to pneumonia and renal failure. The MERS-CoV spike glycoprotein mediates viral attachment to host cells and virus-cell-mediated membrane fusion during infection. It is composed of an S1 subunit, which contains the receptor-binding domain (RBD) that binds to dipeptidyl peptidase-4 (DPP-4), and an S2 subunit containing heptad repeat regions 1 and 2, which are responsible for membrane fusion, as well as a transmembrane domain and a cytoplasmic tail. MERS-CoV is activated by cleavage of the spike glycoprotein into S1 and S2 subunits by various proteases, including TMPRSS2, cathepsin B, cathepsin L, and proprotein convertases, and blockage of this cleavage by protease inhibitors reduces MERS-CoV viral entry into target cells. Cayman's MERS-CoV Spike Glycoprotein Rabbit Monoclonal Antibody (Clone 723) can be used for microneutralization (MN) assays.Synonyms: Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. Immunogen: Recombinant MERS-CoV spike glycoprotein. Clone Designation: 723. Formulation: (Request formulation change), 200 or 500 µg of protein A-affinity purified monoclonal antibody. Storage Buffer: 0.2 µm filtered solution in PBS. Host: Rabbit. Isotype: IgG. Applications: MN. Cross Reactivity: (+) MERS-CoV spike glycoprotein, (+) MERS-CoV spike glycoprotein S1, (+) MERS-CoV spike glycoprotein RBD, (-) MERS-CoV spike glycoprotein S2.